AHA 2019 Pradhan was the discussant of the COLCOT trial. She put the results in the broader perspective of managing inflammation as a means to lower CV risk.
AHA 2019 Dr. Tardif summarizes the study design and results of the COLCOT trial, in which colchicine treatment was found to lower a composite endpoint in patients soon after MI.
AHA 2019 Prof. McMurray presents the results of an analysis of DAPA-HF comparing the effect of dapagliflozin in HF patients with and without T2DM.
AHA 2019 The EVAPORATE trial was conducted to obtain insights in the mechanism of benefit with icosapent ethyl. Prof. Nicholls describes the first findings of the study.
AHA 2019 The AHA has set up a campaign to attack the epidemic of e-cigarette use. Dr. Jessup explains why its effects on youth are devastating.
AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.
AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.
AHA 2019 Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.
AHA 2019 The EVAPORATE study investigated whether an effect of icosapent ethyl on plaque progression can explain part of the CV benefit seen with icosapent ethyl in the REDUCE-IT trial.
AHA 2019 Considering the epidemic of e-cigarette use, particularly among young people, AHA announced substantial investment in research and activities to raise awareness about the risks of vaping.
AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.